Implantable device

• US 8,012,500 B2
• Filed: 11/30/2004
• Issued: 09/06/2011
• Est. Priority Date: 01/12/2000
• Status: Expired due to Fees

• Current Assignee: Beta Cell Technologies Pty., Ltd.
• Original Assignee: Beta-O2 Technologies Ltd.
• Inventors: Bloch, Konstantin, Evron, Yoav, Rotem, Avi, Vardi, Pnina
• Primary Examiner(s): STIGELL, THEODORE J
• Application Number:
  US11/001,556
• Publication Number:
  US 20050136092A1
• Time in Patent Office: 2,471 Days
• Field of Search: 60428801-28804, 604 22- 24, 604/26, 6048901-8911, 424422-425, 424/195.17
• US Class Current: 424/423
• CPC Class Codes: A61F 2/022 Artificial gland structures using bioreactors hemodialysis A61M1/16; hemofiltration A61M1/34; other extracorporeal blood treatment A61M1/36
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 5/14 of the thyroid hormones, e.g. T3, T4
• CPC Class Codes: A61P 5/38 of the suprarenal hormones
• CPC Class Codes: A61P 5/48 of the pancreatic hormones

Abstract

Apparatus is provided including a chamber, which is adapted to be implanted in a body of an individual, the chamber including functional cells and chlorophyll-containing elements comprising chlorophyll of an obligate photoautotroph.

Claims

1. Apparatus comprising:

a chamber, which is adapted to be implanted subcutaneously in a body of an individual, the chamber comprising therein functional cells isolated by the chamber;

an oxygen-provision-facilitating container, adapted to be placed outside the body in a vicinity of skin of the individual, and to convey oxygen through the skin to the functional cells; and

a treatment unit adapted to treat the skin of the individual in a manner that facilitates oxygen transport therethrough.

2. The apparatus according to claim 1, wherein the oxygen-provision-facilitating container is adapted to be placed directly against the skin.

3. The apparatus according to claim 1, wherein the oxygen-provision-facilitating container is adapted to utilize electrolysis to generate oxygen.

4. The apparatus according to claim 1, wherein the chamber is coated with a vascular growth factor.

5. The apparatus according to claim 4, wherein the chamber is coated with one or more factors selected from the group consisting of:

vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), vascular permeability growth factor (VPF), basic fibroblast growth factor (bFGF), and transforming growth factor beta (TGF-.beta.).

6. The apparatus according to claim 1, wherein the oxygen-provision-facilitating container is adapted to be placed within between 1 mm and 15 mm of the skin.

7. The apparatus according to claim 1, wherein the functional cells are capable of releasing a substance, and wherein the chamber comprises one or more walls that are permeable to the substance and are substantially not permeable to the functional cells, such that the substance is released to the body.

8. The apparatus according to claim 7, wherein the functional cells are selected from the list consisting of:

thyroid cells, parathyroid cells, neural cells, ovarian cells, adrenal cells, renal cortex cells, vascular endothelial cells, thymic cells, ovarian cells, testicular cells, genetically engineered cells, cloned cells, and stem cells.

9. The apparatus according to claim 7, wherein the functional cells comprise pancreatic beta cells.

10. The apparatus according to claim 9, wherein the chamber comprises between 10 million and 600 million of the beta cells.

11. The apparatus according to claim 9, wherein the chamber comprises fewer than 10 million of the beta cells.

12. The apparatus according to claim 1, wherein the functional cells are capable of performing at least one action selected from the group consisting of:

absorbing a substance from the body, and degrading a substance from the body.

13. The apparatus according to claim 12, wherein the functional cells comprise hepatic cells.

14. The apparatus according to claim 1, wherein the chamber is shaped so as to define a wafer.

15. The apparatus according to claim 1, wherein the treatment unit comprises an electrical treatment unit.

16. The apparatus according to claim 1, wherein the treatment unit comprises a mechanical treatment unit.

17. The apparatus according to claim 1, wherein the chamber comprises one or more walls, adapted to immunoisolate the functional cells from constituents of the body.

18. The apparatus according to claim 1, wherein the chamber comprises a gel matrix, in which the functional cells are embedded.

19. The apparatus according to claim 1, wherein the chamber comprises an oxygen reservoir.

20. The apparatus according to claim 19, wherein the oxygen reservoir comprises a material that stores and releases oxygen responsively to an oxygen concentration in a vicinity of the reservoir.

21. The apparatus according to claim 20, wherein the oxygen reservoir comprises a perfluorocarbon compound.

22. The apparatus according to claim 20, wherein the oxygen reservoir comprises hemoglobin.

23. The apparatus according to claim 20, wherein the oxygen reservoir comprises silicone.

24. The apparatus according to claim 20, wherein the oxygen reservoir comprises a water-based material.

25. The apparatus according to claim 24, wherein the water-based material comprises a hydrogel.

26. The apparatus according to claim 25, wherein the hydrogel is selected from the list consisting of:

alginate and agarose.

27. The apparatus according to claim 20, wherein the oxygen reservoir comprises a gel matrix.

28. The apparatus according to claim 27, wherein the functional cells are embedded in the gel matrix.

29. The apparatus according to claim 1, wherein the chamber comprises between 10,000 and 600,000 pancreatic islets.

30. Apparatus for use with functional cells, the apparatus comprising:

a chamber, which is adapted to be implanted subcutaneously in a body of an individual, and to hold the functional cells isolated by the chamber;

an oxygen-provision-facilitating container, adapted to be placed outside the body in a vicinity of skin of the individual, and to convey oxygen through the skin to the functional cells; and

a treatment unit adapted to treat the skin of the individual in a manner that facilitates oxygen transport therethrough.